Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, mescaline, DOM +3 moreLSD, mescaline, DOM, DOB, DOI, psilocybin show less
DOET
2,5-dimethoxy-4-ethylamphetamine
DOET (2,5-dimethoxy-4-ethylamphetamine) — also known as Hecate — is a synthetic psychedelic of the phenethylamine class. It is the ethyl homolog of DOM, differing by a single carbon on the 4-position substituent. It activates serotonin receptors in the brain, producing the introspective and perceptual shifts characteristic of classical psychedelics.[1]
DOET (2,5-dimethoxy-4-ethylamphetamine) — also known as Hecate — is a synthetic psychedelic of the phenethylamine class. It is the ethyl homolog of DOM, with comparable duration and a warmer, more introspective character. DOET is a partial 5-HT₂A receptor agonist, producing its effects by altering serotonin-mediated filtering of cognition and perception.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, mescaline, DOM +3 moreLSD, mescaline, DOM, DOB, DOI, psilocybin show less
Alexander Shulgin synthesized DOET at Dow Chemical in the early 1960s, exploring it as a potential mood and cognitive enhancer.[2] Clinical evaluation followed, but the 1967 DOM crisis ended all DOx pharmaceutical development and DOET was placed in US Schedule I in 1973.[3] It remains exceptionally rare in unregulated markets with no approved medical use and no active clinical research.
Subjective effects include enhanced self-awareness, emotional depth, altered associative thinking, and closed-eye visuals.[4] The experience is defined by cognitive and emotional richness — warm and introspective — with notably subdued open-eye visual activity and preserved intellectual clarity even at higher doses. Stimulant body load, appetite suppression, and prolonged wakefulness are characteristic unwanted effects.
DOET produces no physical dependence; rapid tolerance through serotonin downregulation makes compulsive redosing self-limiting.[5] The primary danger is duration-related — sustained cardiovascular stimulation across the extended experience, compounded by a slow onset that invites premature redosing and potentially overwhelming effects.[6] The human evidence base is extremely thin: a handful of clinical studies at sub-hallucinogenic doses and one researcher's self-reports, with no modern clinical data.[7]
History[edit]
Discovery
Alexander Shulgin synthesized DOET at Dow Chemical in the early 1960s as the ethyl homolog of DOM.[2] At low doses it acted as a mood and cognitive enhancer — lifting flexibility and mood without overt psychedelic effects.[8] Dow commissioned formal clinical evaluation of the compound.
Clinical significance
Between 1968 and 1974, researchers published four studies examining DOET in humans at doses up to 4 mg.[7] These documented altered word associations,[9] dose-dependent mood changes, and differing potency between the two mirror-image molecular forms.[10] All studies used sub-hallucinogenic doses; no controlled trial has ever tested DOET at fully psychedelic levels.
Prohibition and modern status
The 1967 DOM crisis — mass distribution of DOM at a San Francisco festival triggering numerous adverse reactions — made further DOx pharmaceutical development politically untenable.[2] DOET was placed in US Schedule I in 1973[3] and remains controlled under the 1971 UN Convention on Psychotropic Substances.[11] No clinical trial program has been registered since.
The name DOET distinguishes the 4-ethyl substituent from 2,5-dimethoxy-4-ethoxyamphetamine (DOE), which would otherwise share the same abbreviation. Shulgin assigned the code name "Hecate" in PiHKAL (1991),[4] where entry #66 remains the only comprehensive published account of DOET's effects at fully psychedelic doses.
Chemistry[edit]
Structural class
DOET belongs to the DOx family — 2,5-dimethoxy-4-substituted amphetamines, a class of phenethylamine psychedelics.[12] It is the ethyl homolog of DOM, placing it between DOM (4-methyl) and DOPR (4-propyl) in the homologous alkyl chain. Greater bulk at the 4-position correlates with stronger receptor binding across the series.[12]
Molecular properties
Its molecular formula is C₁₃H₂₁NO₂ (molecular weight 223.31 g/mol). The molecule consists of a benzene ring with methoxy groups at positions 2 and 5, an ethyl group at position 4, and a 2-aminopropyl side chain at position 1. The hydrochloride salt is a white crystalline solid.[4]
Pharmacology[edit]
Mechanism of action
DOET activates serotonin receptors in the brain — primarily 5-HT₂A, with secondary activity at 5-HT₂C.[1] It acts as a partial agonist, activating these receptors to a fraction of serotonin's full effect.[13] The link between serotonin receptor binding and hallucinogenic potency is well-established across the DOx class.[14][15]
DOET also binds a third serotonin receptor type, 5-HT₂B — shared across DOx compounds — raising a theoretical concern for heart valve effects under sustained or repeated use.[12][16]
Pharmacokinetics
DOET is taken orally. No formal pharmacokinetic studies have been published — half-life, bioavailability, and clearance are all unknown.safety citation needed The likely metabolic pathway is liver processing, inferred from related DOx compounds.[17] The liver enzyme responsible varies greatly between individuals,[4] making dose-response unpredictable.
Neuroscience[edit]
Where it acts
No neuroimaging data have been published for DOET specifically. Based on its confirmed serotonin receptor mechanism, DOET is expected to act on neurons in the cortex, disrupting the brain's default filtering of sensory and cognitive input.citation needed DOx compounds produce distinct patterns of gene activity in the cortex that differ from non-hallucinogenic serotonin agonists, suggesting pathway-specific downstream effects.[18]
DOET's capacity to alter word associations at sub-hallucinogenic doses[9] points to loosening of associative processing — the constraints that normally govern how concepts connect.
Why it matters
The leading model of psychedelic brain effects proposes that serotonergic psychedelics reduce the weight of the brain's top-down expectations, allowing novel associations and sensory signals to surface.citation needed DOET's profile — cognitive flexibility at low doses, full perceptual restructuring at higher doses — fits this framework. Whether DOET promotes new synaptic connections, as documented for other serotonin agonists, has not been tested.citation needed
- Does DOET's extended duration reflect slow clearance from the body, prolonged receptor binding, or both — and does sustained receptor activation produce different neuroplastic outcomes than shorter-acting psychedelics?
- Does DOET's partial (rather than full) receptor activation produce a qualitatively different brain state compared to higher-efficacy agonists like LSD?
Subjective Effects[edit]
DOET's character is defined by what it does to thought and feeling rather than to vision. Introspection deepens, emotional content becomes vivid, and associative thinking loosens — concepts connect in unexpected ways. Open-eye visual effects are notably subdued; intellectual clarity persists even at higher doses.[4]
Compared to DOM, its closest structural sibling, DOET produces a similarly long experience with a reportedly warmer, more body-centered quality.[4] Compared to LSD, the amphetamine backbone adds a persistent stimulant undercurrent — elevated energy, wakefulness, appetite suppression — that ergoline psychedelics lack.
Synthesized by Alexander Shulgin at Dow Chemical in the early 1960s, DOET entered clinical evaluation at Johns Hopkins as a potential "psychic energizer".[2] The DOM (STP) crisis of 1967 terminated all DOx pharmaceutical development, and DOET was placed in US Schedule I in February 1973.[3] No clinical trial has been registered since, and the compound remains rare on unregulated markets.
Subjective effects include enhanced self-awareness, emotional depth, altered associative thinking, and closed-eye visuals.[4] The experience is defined by cognitive and emotional richness with notably subdued open-eye visual activity — a warm, introspective psychedelic state that preserves intellectual clarity even at higher doses. Stimulant body load, appetite suppression, and prolonged wakefulness are characteristic unsought effects.
DOET produces no physical dependence; rapid tolerance through downregulation makes compulsive redosing self-limiting.[5] The primary risk is duration-related: sustained cardiovascular stimulation and psychological vulnerability across the full experience, compounded by a slow onset that invites premature re-dosing.[6] The human evidence base rests on four clinical studies at sub-hallucinogenic doses and one researcher's self-experimentation records[7] — no modern clinical data exist.
History[edit]
Discovery
Alexander Shulgin synthesized DOET at Dow Chemical in the early 1960s as the ethyl homolog of his earlier compound DOM.[2] At sub-hallucinogenic doses it acted as a "psychic energizer" — enhancing mood and cognitive flexibility without overt psychedelic effects.[8] Dow commissioned Solomon Snyder at Johns Hopkins University to conduct formal clinical evaluation.
Clinical significance
Between 1968 and 1974, Snyder and colleagues published four studies examining DOET's effects in humans at doses up to 4 mg.[7] These documented altered word associations,[9] dose-dependent mood changes, and stereospecific activity of the R and S enantiomers.[10] All four studies used sub-hallucinogenic doses; no controlled trial has ever tested DOET at fully psychedelic levels.
Prohibition and modern status
The DOM (STP) crisis of 1967 — triggered by mass distribution of DOM at San Francisco's Human Be-In — caused numerous adverse reactions and made further DOx pharmaceutical development politically untenable.[2] DOET was placed in US Schedule I in February 1973[3] and remains controlled under the 1971 UN Convention on Psychotropic Substances.[11] No clinical trial program has been registered since.
The name DOET distinguishes the 4-ethyl substituent from 2,5-dimethoxy-4-ethoxyamphetamine (DOE), which would otherwise share the same abbreviation. Shulgin assigned the code name "Hecate" in PiHKAL (1991),[4] where entry #66 remains the only comprehensive published account of DOET's effects at fully psychedelic doses.
Chemistry[edit]
Structural class
DOET belongs to the DOx series of 2,5-dimethoxy-4-substituted amphetamines — a family of phenethylamine psychedelics defined by methoxy groups at positions 2 and 5, an alpha-methyl group producing the amphetamine backbone, and a variable substituent at position 4. DOET carries a 4-ethyl group, placing it between DOM (4-methyl) and DOPR (4-propyl) in the homologous alkyl chain. Greater hydrophobicity at position 4 correlates with increased receptor binding across the series.[12]
The alpha-methyl group is essential for psychedelic activity — extending it to alpha-ethyl abolishes hallucinogenic effects in phenylalkylamines, confirming that the 4-position ethyl group is the structure-activity variable determining potency within the DOx series.[13]
Molecular properties
| Molecular formula | C₁₃H₂₁NO₂ |
| Molecular weight | 223.31 g/mol |
The DOET molecule consists of a benzene ring bearing methoxy groups at positions 2 and 5 and an ethyl group at position 4, with a 2-aminopropyl side chain at position 1.
Stereochemistry
DOET has one chirality center at the alpha-carbon, producing R-(−)- and S-(+)-enantiomers. The R-(−)-enantiomer is substantially more potent as a hallucinogen.[10] This preference is the opposite of the amphetamine stimulant pattern, where S-(+) (dextroamphetamine) is typically more active, and is consistent with the general rule for phenylalkylamine hallucinogens.[13]
Physical properties
The hydrochloride salt is a white crystalline solid with a melting point of 194–195 °C.[4] Solubility, stability, and degradation pathways have not been characterized in published literature.
Pharmacology[edit]
Mechanism of action
DOET produces its psychedelic effects primarily through activation of 5-HT₂A serotonin receptors, with secondary activity at 5-HT₂C receptors.[1] The strong correlation between serotonin receptor binding and hallucinogenic potency across the DOx class confirms this mechanism.[14][15]
At 5-HT₂A, DOET functions as a partial agonist — activating the receptor to a fraction of serotonin's full effect.[16] Its behavioral effects are blocked by selective 5-HT₂A antagonists in animal models,[17][18] confirming receptor dependence. Broader receptor screening indicates DOx compounds interact with dozens of binding sites beyond the canonical serotonin targets.[19]
DOET also binds 5-HT₂B receptors, a property shared across the DOx series that raises a theoretical cardiac concern under sustained or repeated use.[12][20]
Pharmacokinetics
DOET is taken orally. Effects emerge gradually over 1–3 hours, peak at 3–5 hours, and persist for 14–20 hours depending on dose.[4]
No formal pharmacokinetic studies have been published. Plasma half-life, bioavailability, and clearance are unknown. The 14–20-hour experience duration derives entirely from self-report data and has not been corroborated by blood concentration measurements.safety citation needed
The presumed primary metabolic pathway is liver-mediated O-demethylation, inferred from closely related DOx compounds.[21] The liver enzyme responsible is highly variable between individuals — some people metabolize DOx compounds slowly (potentially prolonging and intensifying effects), while others clear them rapidly. Combined with Shulgin's documentation of substantial individual variation in DOET sensitivity,[4] this metabolic variability is a clinically relevant source of dose-response unpredictability.
Neuroscience[edit]
Where it acts
No neuroimaging data have been published for DOET specifically. Based on its confirmed serotonin 2A receptor agonist mechanism, DOET is expected to act on serotonin receptors concentrated on cortical pyramidal neurons, disrupting default mode network integrity and reducing the brain's filtering of sensory and cognitive input.citation needed DOx compounds produce distinct gene expression patterns in cortex that differ from non-hallucinogenic 5-HT₂A agonists, suggesting pathway-specific downstream effects.[22]
DOET's documented capacity to alter word associations at sub-hallucinogenic doses[9] points to modulation of associative processing networks — loosening the constraints that normally govern how concepts connect.
Why it matters
The REBUS (Relaxed Beliefs Under Psychedelics) model proposes that serotonergic psychedelics reduce the weight of the brain's top-down predictions, allowing novel associations and sensory signals to surface.citation needed DOET's profile — cognitive flexibility at low doses, full perceptual restructuring at higher doses — fits dose-dependent dynamics under this framework. Whether DOET promotes structural neuroplasticity (new synaptic connections) via the same pathways documented for other 5-HT₂A agonists has not been tested.citation needed
- Does DOET's extended 14–20-hour duration reflect slow clearance from the body, prolonged receptor binding, or both — and does sustained receptor activation produce different neuroplastic outcomes than shorter-acting psychedelics?
- Does DOET's partial (rather than full) receptor activation produce a qualitatively different brain state compared to higher-efficacy agonists like LSD?
Subjective Effects[edit]
DOET occupies an unusual position among serotonergic psychedelics: introspection, emotional openness, and enhanced associative thinking dominate the experience, while open-eye visual effects remain notably subdued.[4] At lower doses, cognitive shifts and mood elevation predominate without perceptual distortion;[7] at higher doses, closed-eye visuals and deep emotional engagement emerge, but intellectual clarity persists. Individual sensitivity varies considerably, likely reflecting differences in liver enzyme activity.[21]
Relative to DOM, its closest structural sibling, DOET produces a comparably long experience with a reportedly warmer, more body-centered quality.[4] Compared to LSD, the amphetamine backbone contributes a persistent stimulant undercurrent — cardiovascular activation, wakefulness, appetite suppression — absent from ergoline psychedelics.
Effect Grid
The transition zone between sub-hallucinogenic enhancement and threshold psychedelic effects. Mood elevation becomes more pronounced, with possible mild visual disturbances and heightened body awareness. Cognitive flexibility and emotional enhancement increase noticeably, and introspective thinking deepens.
Stimulation becomes apparent — wakefulness, mild muscle tension, and temperature sensitivity. Appetite suppression is typical. The amphetamine-derived body load begins asserting itself.
Duration reaches the full 14–20-hour range. Sleep is impossible for at least 12 hours. Individual sensitivity varies dramatically at this level — CYP2D6 metabolic polymorphism means a dose sub-perceptual for one person may produce clearly psychedelic effects in another.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color alteration · Visual breathing · Brightness alteration · Light sensitivity · Environmental patterning · Music enhancement · Tracers · Sound sensitivity · Holotropic state · Visual diffraction · Visual melting · Perspective distortion · Depth perception distortion · Peripheral vision distortion · Spatial disorientation · Symmetrical texture repetition · After-images · Auditory enhancement · Visual haze / noise · Touch enhancement · Visual acuity enhancement · Synesthesia · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Sleep-transition hallucinations · Dreaming suppression · Vestibular distortion · Visual processing acceleration · Olfactory enhancement · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Visual recursion · Object transformations · Object activation · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Auditory hallucinations · Visual flipping
Environmental patterning · Music enhancement · Tracers · Sound sensitivity · Holotropic state · Visual diffraction · Visual melting · Perspective distortion · Depth perception distortion · Peripheral vision distortion · Spatial disorientation · Symmetrical texture repetition · After-images · Auditory enhancement · Visual haze / noise · Touch enhancement · Visual acuity enhancement · Synesthesia · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Sleep-transition hallucinations · Dreaming suppression · Vestibular distortion · Visual processing acceleration · Olfactory enhancement · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Visual recursion · Object transformations · Object activation · External hallucinations · Perspective hallucinations · Environmental orbism / cubism · Auditory hallucinations · Visual flipping
Pupil dilation · Appetite suppression · Dry mouth · Muscle tension · Restlessness · Excessive sweating · Spontaneous body sensations · Tingling / electric sensations · Physical fatigue · Body high · Body scan awareness · Headache · Nausea · Heart rate perception changes · Bruxism · Dehydration sensation · Bodily pressures · Body schema distortion · Vibrations / buzzing · Breathing alteration · Respiratory stimulation · Dizziness · Nasal congestion · Laughter fits · Bodily lightness · Tactile euphoria · Trembling · Sexual arousal enhancement · Involuntary body movements · Nystagmus (eye wobbles) · Vomiting · Bodily dissociation
Restlessness · Excessive sweating · Spontaneous body sensations · Tingling / electric sensations · Physical fatigue · Body high · Body scan awareness · Headache · Nausea · Heart rate perception changes · Bruxism · Dehydration sensation · Bodily pressures · Body schema distortion · Vibrations / buzzing · Breathing alteration · Respiratory stimulation · Dizziness · Nasal congestion · Laughter fits · Bodily lightness · Tactile euphoria · Trembling · Sexual arousal enhancement · Involuntary body movements · Nystagmus (eye wobbles) · Vomiting · Bodily dissociation
Immersion enhancement · Openness enhancement · Pattern recognition enhancement · Conceptual thinking · Thought connectivity · Thought acceleration · Multiple thought streams · Cognitive flexibility · Cognitive euphoria · Cognitive fatigue · Thought loops · Increased nature relatedness · Creativity enhancement · Information processing suppression · Cognitive impairment · Confusion · Memory fragmentation · Synchronicity · Humor enhancement · Analysis enhancement · Focus enhancement · Motivation enhancement · Thought disorganization · Memory replays · Memory suppression · Focus suppression · Cognitive dysphoria · Information processing enhancement · Thought organization · Motivation suppression · Delusions of sobriety · Language suppression · Delusions
Conceptual thinking · Thought connectivity · Thought acceleration · Multiple thought streams · Cognitive flexibility · Cognitive euphoria · Cognitive fatigue · Thought loops · Increased nature relatedness · Creativity enhancement · Information processing suppression · Cognitive impairment · Confusion · Memory fragmentation · Synchronicity · Humor enhancement · Analysis enhancement · Focus enhancement · Motivation enhancement · Thought disorganization · Memory replays · Memory suppression · Focus suppression · Cognitive dysphoria · Information processing enhancement · Thought organization · Motivation suppression · Language suppression · Delusions
Anxiety · Simultaneous emotions · Empathy enhancement · Catharsis · Dysphoria · Irritability · Anhedonia · Mania
Catharsis · Dysphoria · Irritability · Anhedonia
Social connection · Trust enhancement · Flow state · Sociability enhancement · Depersonalization · Ego inflation · Automaticity · Communication suppression · Communication enhancement · Sociability suppression · Social disconnection · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings
Depersonalization · Ego inflation · Automaticity · Communication suppression · Communication enhancement · Sociability suppression · Social disconnection · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings
Time cessation
Entity contact · Transpersonal visions · Transpersonal memory access · Death-rebirth sequence · Cessation · Voidness
Cessation · Voidness
Recursive awareness
Timeline
Minimal perceptible effects; possible slight mood shift or somatic awareness. Most users report uncertainty about whether effects have begun.
Gradual emergence of mood enhancement, body awareness, and mild stimulation. Anxious anticipation is common during this slow build.
Maximum emotional depth and cognitive enhancement. Closed-eye visuals at psychedelic doses; introspective engagement at its strongest.
Sustained effects at slightly reduced intensity. Emotional engagement and body stimulation persist; wakefulness is pronounced.
Gradual return toward baseline over many hours. Stimulation and wakefulness persist well beyond subjective psychedelic effects; residual emotional sensitivity.
Residual mood effects, physical fatigue, and reflective state. Possible insomnia despite tiredness.
⚠ Do not drive or operate machinery for at least 20 hours after ingestion — residual cognitive and perceptual effects may persist beyond the subjective experience.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · mesc · DOM
Toxicity
No lethal dose has been established for DOET in any species.safety citation needed No published case reports of overdose or death have been identified. The compound is recognized by forensic toxicologists,[19] but rarity of use likely accounts for the absence of reports.
Cardiovascular effects
DOET raises blood pressure and body temperature. These effects are confirmed as serotonin-mediated in animal models[6] and are expected across the DOx class.
Cardiac valve risk
DOx compounds bind a serotonin receptor type linked to heart valve thickening — the same target implicated in damage caused by the weight-loss drug fenfluramine.[12] No case of DOET-associated valve damage has been reported, but the pharmacological basis for concern exists at the class level.[1]
Duration-related risk
DOET's extended duration[4] creates compounding risk if additional doses are taken during the slow 1–3-hour onset or if stimulants are co-administered. Cardiovascular stimulation may persist well beyond the subjective psychedelic peak.
Psychological risks
Clinical studies documented anxiety at higher sub-hallucinogenic doses approaching 4 mg.[7] At fully psychedelic doses, the extended duration creates prolonged vulnerability to anxiety, paranoia, and difficult psychological states, particularly without supportive companionship.[4]
The slow onset creates specific risk of premature redosing, potentially producing unexpectedly intense experiences. Persistent perceptual changes and psychosis have not been documented for DOET specifically; these risks are inferred from class membership with other serotonergic psychedelics.safety citation needed
Tolerance and dependence
Tolerance develops rapidly through serotonin downregulation — measurable within 24 hours of a single dose in animal models.[5] Cross-tolerance occurs with LSD, mescaline, and DOM due to the shared receptor mechanism. Tolerance typically reverses within several days to one week.
No physical dependence, withdrawal, or compulsive use pattern has been documented for DOET or the DOx class.
Drug Interactions
MAOIs: No DOET-specific data exist. Combining elevated brain serotonin with a serotonin-activating stimulant compound is potentially dangerous.safety citation needed
CYP2D6 inhibitors: Drugs including fluoxetine and paroxetine inhibit the liver enzyme that processes DOET, potentially prolonging and intensifying effects.[17]
SSRIs and SNRIs: Long-term serotonergic antidepressant use reduces the subjective effects of serotonergic psychedelics through receptor desensitization.[20]
Stimulants: Combining amphetamines, cocaine, or other stimulants with DOET is expected to raise blood pressure and body temperature further, given DOET's documented cardiovascular effects.[6]
5-HT₂A antagonists: Antipsychotics that block serotonin receptors (ketanserin, risperidone) cancel DOx psychedelic effects.[21][22] Older antipsychotics such as chlorpromazine may worsen rather than help — their use during the 1967 DOM crisis worsened some patients' responses.
Lithium: No published interaction data exist for DOET with lithium. Potentiation of psychedelic effects has been anecdotally reported for LSD.safety citation needed
Contraindications
6 knownCardiovascular conditions: DOET's blood pressure-raising and temperature-elevating effects[6] and theoretical valve risk[12] make it inadvisable for those with high blood pressure, irregular heart rhythm, or existing heart valve disease.
Psychiatric vulnerability: As a serotonergic psychedelic, DOET carries the class-level risk of triggering or worsening psychotic disorders, mania, or severe anxiety in predisposed individuals.safety citation needed
MAOI co-administration: Combining MAOIs with a serotonin-activating stimulant compound is a relative contraindication.safety citation needed
Liver impairment: Significant liver impairment could slow DOET's clearance and prolong effects.[17]
Pregnancy and lactation: No reproductive safety data exist. DOET is contraindicated during pregnancy and breastfeeding as a precautionary measure.safety citation needed
Harm Reduction[edit]
Forms & Identification
DOET is exceptionally rare in unregulated markets. When encountered, it appears as white powder or pressed tablets. The active dose range demands milligram-precision measurement — standard kitchen or postal scales are wholly inadequate.
Because DOx compounds look identical as powders, reagent testing alone cannot confirm identity with certainty. Laboratory analysis (GC-MS or similar) is the only reliable identification method. Any substance sold as DOET should be treated as unverified until analytically confirmed.
Guidelines
- Test any substance claimed to be DOET with reagent kits and, ideally, laboratory analysis before use
- Use a milligram-precision scale (0.001 g resolution) for dosing — never estimate by eye
- Start with the lowest dose within the reported active range; individual sensitivity varies substantially due to metabolic differences
- Do not re-dose during the 1–3-hour onset — the slow onset is the most common cause of accidental over-dosing with DOx compounds
- Have a sober, trusted companion present for the full duration
- Prepare food, water, and comfort items in advance — appetite suppression and stimulant effects persist throughout
- Clear the full following day; sleep may be difficult for several hours after subjective effects resolve
Set & Setting
DOET's extended duration demands that the setting be sustainable for an entire waking day — comfortable, private, with access to food, water, temperature control, and a bathroom. A sober companion who understands the timeline is strongly recommended; psychological difficulty across a very long experience is far more draining than during a shorter one.
Pre-existing anxiety, unresolved emotional conflict, or physical illness can all be amplified across the extended duration. Begin only when rested, hydrated, and in a stable psychological state with no obligations for 24 hours.
Aftercare & integration. The day after a DOET experience is a recovery day. Sleep disruption is common — allow rest without alarm clocks or obligations. Eat nutrient-dense food and rehydrate, as appetite suppression during the experience may leave a caloric deficit.
Journaling within 24–48 hours helps capture insights before they fade. If the experience brought up difficult emotions or memories, talk through them with a trusted person. For persistent distress lasting more than a week, consider seeking a therapist experienced with psychedelic integration.
Recovery & Support
DOET does not produce physical dependence, and compulsive use patterns are unlikely given its extended duration and rapid tolerance. If psychedelic use is becoming a pattern of avoidance rather than exploration, or if experiences are consistently distressing rather than insightful, consider stepping back.
Resources for support include the Fireside Project (62-FIRESIDE / 623-473-7433), a psychedelic peer support line, and MAPS integration therapist directories for finding professionals experienced with psychedelic-related concerns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most DOET experiences involve discomfort but resolve safely. Seek immediate help if any of the following occur: chest pain or pressure, severe headache with confusion, seizure or convulsions, body temperature high enough to feel through clothing, self-harm behavior, or complete loss of contact with reality.
Immediate steps
- 1. Call emergency services if any red-flag symptoms are present
- 2. Move the person to a quiet, cool environment
- 3. Do not restrain unless there is immediate danger of self-harm
- 4. Offer calm reassurance — remind them what they took and that the effects will end
- 5. Monitor breathing and body temperature while waiting for help
- 6. Do not administer chlorpromazine or other older antipsychotics — these may worsen DOx reactions
What to tell the dispatcher
State the substance name (DOET or DOx compound), estimated dose, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
DOET is controlled in most major jurisdictions through scheduling decisions made in the 1970s following the broader prohibition of substituted amphetamines and hallucinogens. It is listed in Schedule I of the 1971 UN Convention on Psychotropic Substances,[11] obligating signatory nations to apply the strictest control measures. No jurisdiction has approved DOET for any medical use.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA code 7399; placed February 1973[3] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled via generic phenethylamine structural definition; any alpha-methylphenethylamine with ring substituents is classified as Class A[23] |
| Australia | Schedule 9 Prohibited Substance | Listed under the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP)[24] |
| Canada | Likely controlled (CDSA) | Not explicitly listed; probable control via analogue provisions for amphetamine derivativescitation needed |
| European Union | Varies by member state | No EU-wide scheduling; individual member states may control under national analogue provisions or specific schedules |
| International | Schedule I (UN Convention on Psychotropic Substances, 1971) | Signatory nations obligated to apply strictest controls[11] |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · mesc · DOM
Toxicity
No lethal dose has been established for DOET in any species.safety citation needed No published case reports of overdose or death have been identified. The compound is recognized by forensic toxicologists,[23] but the absence of case reports likely reflects rarity of use rather than absence of risk.
Cardiovascular effects
DOET raises blood pressure and body temperature in animal models, effects confirmed as serotonin-mediated.[6] These cardiovascular and thermoregulatory effects are expected for all DOx compounds as a class.
Cardiac valve risk
DOx compounds bind 5-HT₂B receptors,[12] the same target linked to heart valve thickening caused by fenfluramine-class drugs. No clinical case of DOET-associated valve damage has been reported, but the pharmacological basis for concern exists at the class level.[1]
Duration-related risk
DOET's 14–20-hour duration[4] creates compounding risk if additional doses are taken during the slow 1–3-hour onset or if stimulants are co-administered. Cardiovascular stimulation may persist well beyond the subjective psychedelic peak.
Psychological risks
Clinical studies documented anxiety at higher sub-hallucinogenic doses approaching 4 mg.[7] At fully psychedelic doses, the 14–20-hour duration creates prolonged vulnerability to anxiety, paranoia, and difficult psychological states, particularly without supportive companionship.[4]
The 1–3-hour onset delay creates specific risk of premature re-dosing, potentially producing unexpectedly intense experiences. No data on persistent perceptual changes (HPPD) or psychosis specific to DOET have been published. These risks are inferred from class membership with other serotonergic psychedelics.safety citation needed
Tolerance and dependence
Tolerance develops rapidly through serotonin downregulation — measurable within 24 hours of a single dose in animal models.[5] Cross-tolerance occurs with other serotonergic psychedelics (LSD, mescaline, DOM) due to the shared receptor mechanism.
No physical dependence, withdrawal, or compulsive use pattern has been documented for DOET or the DOx class. Rapid tolerance and extended duration make compulsive redosing unlikely. Tolerance typically reverses within several days to one week.
Drug Interactions
MAOIs: No DOET-specific data exist. The combination of elevated brain serotonin with a serotonin receptor agonist carrying stimulant cardiovascular properties is potentially dangerous.safety citation needed
CYP2D6 inhibitors: Drugs including fluoxetine and paroxetine could slow DOET's metabolism, potentially prolonging and intensifying effects.[21]
SSRIs and SNRIs: Chronic serotonergic antidepressant use attenuates the subjective effects of serotonergic psychedelics through receptor desensitization.[24]
Stimulants: Concurrent use of amphetamines, cocaine, or other stimulants with DOET is expected to produce additive cardiovascular effects — elevated blood pressure and body temperature — given DOET's documented pressor and hyperthermic actions.[6]
5-HT₂A antagonists: Antipsychotics with serotonin-blocking activity (ketanserin, risperidone) block DOx psychedelic effects.[17][18] Older antipsychotics such as chlorpromazine may not be appropriate — their use during the 1967 DOM crisis worsened some patients' responses.
Lithium: No published interaction data exist for DOET with lithium. Lithium potentiation of psychedelic effects has been anecdotally reported for LSD.safety citation needed
Contraindications
6 knownCardiovascular conditions: DOET's blood pressure-raising and temperature-elevating effects[6] and theoretical valve risk[12] make it inadvisable for individuals with high blood pressure, irregular heart rhythm, or existing heart valve disease.
Psychiatric vulnerability: As a serotonergic psychedelic, DOET carries the class-level risk of triggering or worsening psychotic disorders, mania, or severe anxiety in predisposed individuals.safety citation needed
MAOI co-administration: The combination of MAOIs with a serotonin agonist carrying stimulant cardiovascular properties represents a relative contraindication.safety citation needed
Liver impairment: Given DOET's presumed liver-dependent metabolism,[21] significant liver impairment could slow clearance and prolong effects.
Pregnancy and lactation: No reproductive safety data exist. DOET is contraindicated during pregnancy and breastfeeding as a precautionary measure.safety citation needed
Harm Reduction[edit]
Forms & Identification
DOET is exceptionally rare in unregulated markets. When encountered, it may appear as white powder or in pressed tablets. The active dose range of 2–7 mg demands milligram-precision measurement — standard kitchen or postal scales are wholly inadequate. Because DOx compounds are visually indistinguishable from one another as powders, reagent testing alone cannot confirm identity with certainty. Laboratory analysis (GC-MS or similar) provides the only reliable identification. Any substance sold as DOET should be treated as unverified until analytically confirmed.
Guidelines
- Test any substance claimed to be DOET with reagent kits and, ideally, laboratory analysis before use
- Use a milligram-precision scale (0.001 g resolution) for dosing — never estimate by eye
- Start with the lowest dose within the reported active range; individual sensitivity varies substantially due to metabolic differences
- Do not re-dose during the 1–3-hour onset — the slow onset is the most common cause of accidental over-dosing with DOx compounds
- Have a sober, trusted companion present for the full duration
- Prepare food, water, and comfort items in advance — appetite suppression and stimulant effects persist throughout
- Clear the full following day; sleep may be difficult for several hours after subjective effects resolve
Set & Setting
DOET's 14–20-hour duration demands particular attention to environment. The setting must be sustainable for an entire waking day — a comfortable, private space with access to food, water, temperature control, and a bathroom. A sober companion who understands the timeline is strongly recommended, as psychological difficulty during a 16-hour experience can be far more draining than during a 6-hour one.
Mental preparation matters. Pre-existing anxiety, unresolved emotional conflict, or physical illness can all be amplified across the extended duration. Begin only when rested, hydrated, and in a stable psychological state with no obligations for 24 hours.
Aftercare & integration. The day after a DOET experience is a recovery day. Sleep disruption is common — allow the body to rest without alarm clocks or obligations. Eat nutrient-dense food and rehydrate, as appetite suppression during the experience may leave a caloric deficit.
Journaling within 24–48 hours helps capture insights before they fade. If the experience brought up difficult emotions or memories, talk through them with a trusted person. For persistent distress lasting more than a week, consider seeking a therapist experienced with psychedelic integration.
Recovery & Support
DOET does not produce physical dependence, and compulsive use patterns are unlikely given its extended duration and rapid tolerance. If psychedelic use is becoming a pattern of avoidance rather than exploration, or if experiences are consistently distressing rather than insightful, consider stepping back.
Resources for support include the Fireside Project (62-FIRESIDE / 623-473-7433), a psychedelic peer support line, and MAPS integration therapist directories for finding professionals experienced with psychedelic-related concerns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most DOET experiences involve discomfort but resolve safely. Seek immediate help if any of the following occur: chest pain or pressure, severe headache with confusion, seizure or convulsions, body temperature high enough to feel through clothing, self-harm behavior, or complete loss of contact with reality.
Immediate steps
- 1. Call emergency services if any red-flag symptoms are present
- 2. Move the person to a quiet, cool environment
- 3. Do not restrain unless there is immediate danger of self-harm
- 4. Offer calm reassurance — remind them what they took and that the effects will end
- 5. Monitor breathing and body temperature while waiting for help
- 6. Do not administer chlorpromazine or other older antipsychotics — these may worsen DOx reactions
What to tell the dispatcher
State the substance name (DOET or DOx compound), estimated dose, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
DOET is controlled in most major jurisdictions, primarily through scheduling decisions made in the 1970s following the broader prohibition of substituted amphetamines and hallucinogens. It is listed in Schedule I of the 1971 UN Convention on Psychotropic Substances,[11] obligating signatory nations to apply the strictest control measures. No jurisdiction has approved DOET for any medical use.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA code 7399; placed February 1973[3] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled via generic phenethylamine structural definition; any alpha-methylphenethylamine with ring substituents is classified as Class A[25] |
| Australia | Schedule 9 Prohibited Substance | Listed under the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP)[26] |
| Canada | Likely controlled (CDSA) | Not explicitly listed; probable control via analogue provisions for amphetamine derivativescitation needed |
| European Union | Varies by member state | No EU-wide scheduling; individual member states may control under national analogue provisions or specific schedules |
| International | Schedule I (UN Convention on Psychotropic Substances, 1971) | Signatory nations obligated to apply strictest controls[11] |
Frequently asked questions
How long does DOET last?
Total duration by route of administration — Oral: 14 – 20 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for DOET?
Psychedex publishes a dosage table for DOET on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with DOET?
The highest-severity documented interactions for DOET: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is DOET addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for DOET: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, mescaline, DOM, DOB, DOI, psilocybin. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcNelson DL, Lucaites VL, Wainscott DB, Glennon RA (1999) Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. — Naunyn-Schmiedeberg's Archives of Pharmacology PMID:9933142
- [2] ^abcTrout K, Daley PF (2024) The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP) — Drug Testing and Analysis doi:10.1002/dta.3667
- [3]
- [4]
- [5] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6] ^abcdHuang J, Ho BT (1975) Some pharmacological actions of 2,5-dimethoxy-4-ethylamphetamine (DOET) in rats and mice. — The Journal of Pharmacy and Pharmacology PMID:235610
references
- [1] ^abcNelson DL, Lucaites VL, Wainscott DB, Glennon RA (1999) Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. — Naunyn-Schmiedeberg's Archives of Pharmacology PMID:9933142
- [2] ^abcTrout K, Daley PF (2024) The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP) — Drug Testing and Analysis doi:10.1002/dta.3667
- [3]
- [4]
- [5] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6] ^abcdHuang J, Ho BT (1975) Some pharmacological actions of 2,5-dimethoxy-4-ethylamphetamine (DOET) in rats and mice. — The Journal of Pharmacy and Pharmacology PMID:235610